PTGX vs TECH
Protagonist Therapeutics, Inc. vs Bio-Techne — AI-powered side-by-side comparison
PTGX
Protagonist Therapeutics, Inc.
70
Buy
VS
| Metric | PTGX | TECH |
|---|
| AI Score |
70
|
71
|
| Price |
$155.12
|
$72.42
|
| P/E Ratio |
127.33×
|
61.88×
|
| ROE |
-21.2%
|
8.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
99.9%
|
65.8%
|
| Debt / Equity |
0.01×
|
0.13×
|
| Dividend Yield |
0.0%
|
0.4%
|
| RSI (14) |
75.9
|
63.6
|
| Beta |
1.794
|
1.277
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for PTGX versus TECH.
TECH leads by 1 points.
TECH scores 71/100 (Buy) versus PTGX at 70/100 (Buy).
PTGX Committee View
80% agreement
5 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- RSI at 76 is in overbought territory — Technical
- Weekly RSI at 87 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 20.7% signals elevated volatility — Risk
TECH Committee View
80% agreement
5 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical